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SUMMARY – The objective of this review is to assess the incidence of postoperative acute renal 
failure that necessitates the application of hemofiltration and to determine the factors that influence 
the outcome in patients undergoing surgical repair of abdominal aortic aneurysm. In addition, the 
review aims to assess the outcomes of postoperative early hemofiltration as compared to late intensive 
hemofiltration. Different forms of renal replacement therapies for use in abdominal aortic aneurysm 
surgery patients are discussed. Electronic literature searches were performed using Pubmed, Medli-
ne, Embase, Sumsearch, Cinahil, The Cochrane Central Register of Controlled Trials and Excerpta 
Medica. The search identified 419 potentially eligible studies, of which 119 were excluded based on 
the title and abstract. Of the remaining 300 studies, full articles were collected and re-evaluated. 
Forty-five articles satisfied our inclusion criteria, of which only 12 were of the IA Level of evidence. 
The search results indicated that the underlying disease, its severity and stage, the etiology of acute 
renal failure, clinical and hemodynamic status of the patient, the resources available, and different 
costs of therapy might all influence the choice of the renal replacement therapy strategy. However, 
clear guidelines on renal replacement therapy duration are still lacking. Moreover, it is not known 
whether in acute renal failure patients undergoing abdominal aortic aneurysm surgery, renal repla-
cement therapy modalities can eliminate significant amounts of clinically relevant inflammatory me-
diators. This review gives current information available in the literature on the possible mechanisms 
underlying acute renal failure and recent developments in continuous renal replacement treatment 
modalities. 
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Introduction
The objective of this review is three-fold: 1) to as-
sess the incidence of postoperative acute renal failure 
(ARF) that necessitates the application of hemofil-
tration; 2) to determine the factors that influence the 
outcome in patients undergoing surgical repair of ab-
dominal aortic aneurysm (AAA); and 3) to assess the 
outcomes of postoperative early hemofiltration as com-
pared to late intensive hemofiltration. ARF occurs in 
approximately 2% of patients with normal preoperative 
renal function who undergo endovascular abdominal 
aortic aneurysm repair (EVAR), up to 10% after open 
surgical repair (OSR)1. For patients with preoperative 
renal impairment, the perioperative mortality rate is 
high, 27% following EVAR, to up to 66% after OSR2. 
To explore the differential application and outcomes 
of EVAR and open surgical AAA repair, we used data 
from the Nationwide Inpatient Sample (NIS), the 
largest all-payer inpatient care database in the United 
States, as well as electronic literature searches using 
Pubmed, Medline, Embase, Sumsearch, Cinahil, The 
Cochrane Central Register of Controlled Trials and 
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Excerpta Medica. Renal injury during cardiac surgery 
appears to be mechanistically related to the pre-exist-
ing renal dysfunction, diabetes mellitus, ventricular 
dysfunction, older age, hypertension, microembolic 
and macroembolic processes, inflammatory mediators, 
sensitivity to sympathetic stimulation, and perturba-
tion in renovascular resistance and flow3-5. Although 
ARF incidence is relatively low, it is of major concern 
because, when it occurs, it is associated with high 
morbidity and mortality. Based on the outcome data 
on EVAR, renal implications of the procedure need 
to be scrutinized. Although patients receiving EVAR 
are spared from ischemic insult of the aortic cross-
clamping and have less perioperative hemorrhage, the 
potential nephrotoxicity of intravenous contrast must 
be considered6. The establishment of continuous renal 
replacement therapy (CRRT) has been proposed as 
a means of reducing the in-hospital mortality in pa-
tients who develop postoperative ARF. In this review, 
we focus primarily on the literature dealing with renal 
complications occurring in the perioperative phase of 
abdominal aortic surgery. There is currently a unani-
mous agreement that renal complications have a se-
vere impact upon the patient’s management and out-
come. Specifically, it has an impact on the method of 
renal replacement therapy (RRT), i.e. dialysis (based 
on the diffusion principle) or hemofiltration (based 
on convention), the dose of renal replacement therapy 
(urea KT/V for dialysis vs  hemofiltration flow (mL/
kg/h), and timing of RRT (early vs late). Here we dis-
cuss the mechanisms leading to the induction of ARF 
postoperatively and focus on the different modalities 
of CRRT available. 
Methods
Database 
Electronic database search was made through 
biomedicine databases, from 1977 to 2008, such as 
Pubmed, Medline, Embase, Sumsearch, Cinahil, The 
Cochrane Central Register of Controlled Trials and 
Excerpta Medica. To determine the clinical value of 
a study (Level of evidence) we utilized a method cur-
rently suggested in evidence-based medicine (Table 1).
We performed search with mash technique us-
ing the following key words: renal replacement ther-
apy, acute renal failure, abdominal aortic aneurysm, 
oxidative stress, inflammation. The dataset provides 
detailed information on patient demographics, out-
comes (e.g., in-hospital mortality, length of stay), total 
Table 1. Method utilized in evidenced based medicine to determine the clinical value of a study (Level 
of evidence)
Level of evidence Description (type of study)
IA Systematic Review (or Meta-analysis) (with homogeneity) of Randomized Controlled Trials (RCT)
IB Individual RCT (with narrow Confidence Interval)
IIA Evidence from at least one controlled study without randomization. Sys-tematic Review (with homogeneity) of cohort studies
IIB Evidence from at least one other type of quasi-experimental study. Indi-vidual cohort study (including low quality RCT; e.g., <80% follow-up)
III
Evidence from non-experimental descriptive studies such as comparative 
studies, correlation studies, and case-control studies. Systematic reviews 
(SR) (with homogeneity) of case-control studies. Individual Case-Control 
Study 
IV
Evidence from expert committee reports or opinions or clinical experience 
of respected authorities, or both. Case-series (and poor quality cohort and 
case-control studies). Expert opinion without explicit critical appraisal, or 
based on physiology, bench research or "first principles"
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charges, hospital characteristics, and insurance status. 
In addition, hospital and discharge weights are pro-
vided to extrapolate estimates to a national level and 
ensure that standard errors that are used for the analy-
ses reflect the sampling scheme of the dataset. In the 
review, we included questions designed to address the 
extent to which the information on baseline character-
istics and study design suggested treatment modalities 
were comparable using the Level of evidence method. 
A score ranging from 1-5 was generated where „1“ 
indicated that the groups were „definitely different“, 
„3“ indicated „uncertainty“, and „5“ indicated that the 
groups were „definitely equal“.
Patient population 
In brief, we identified all discharges of patients >18 
years of age with a primary diagnosis of an unrup-
tured AAA (open repair, n=3936; endovascular re-
pair, n=2678). Hospitalizations in which an aortorenal 
bypass was performed in addition to the AAA repair 
(n=42) were excluded to evaluate the specific impact 
of the aortic procedure on kidney function. Patients 
receiving maintenance dialysis (n=56) were excluded 
from the analysis by identifying codes associated with 
end-stage renal disease and removing all discharges 
in which there was a dialysis code but no concurrent 
diagnosis of ARF.
Exposure, outcome, and covariates
Procedure type 
The type of the procedure, i.e. EVAR vs open AAA 
repair, was the key exposure of interest. The primary 
outcome was postprocedure ARF. ARF requiring he-
modialysis was also considered. We evaluated patient 
demographic and clinical characteristics that might 
contribute to the risk of ARF. These included patient 
age, gender, and key comorbidities including chronic 
kidney disease, diabetes mellitus, chronic lung disease, 
congestive heart failure, and chronic liver disease7-15. 
We also adjusted for hospital type (rural, urban-
teaching, urban-nonteaching) and procedure volume, 
the latter dichotomized as above and below the medi-




The search identified 419 potentially eligible stud-
ies of which 119 were excluded based on title and ab-
stract. Of the remaining 300 studies, full articles were 
collected and re-evaluated. Forty-five articles satisfied 
our inclusion criteria, of which only 12 were of the 
IA Level of evidence. The search results pointed out 
that the underlying disease, its severity and stage, the 
etiology of ARF, clinical and  hemodynamic status of 
the patient, the resources available, and different costs 
of therapy may all influence the choice of the renal 
replacement therapy strategy. Exactly 6516 patients 
were included in the analysis of published reports. We 
were able to assess baseline severity of illness only in 
12 studies (number of patients 1400; Level of evidence 
IA). The results and the overall quality and severity 
scores of the blinded review are presented in Table 2.
Patient population
With respect to non-acute kidney injury(non-
AKI), there appeared to be a stepwise increase in 
the relative risk (RR) of death going from the risk 
(RR=2.40) through injury (RR=4.15) to failure (6.37, 
P<0.0001 all); however, the element of patient popu-
lation heterogeneity was noted on interpreting the 
results. Among 6516 patients that met the inclusion 
criteria, 3865 (59.3%) were for open AAA repair 
and 2651 (40.7%) were for EVAR. Patients receiving 
EVAR were older, more likely to be male and to be di-
agnosed with diabetes mellitus, but were less likely to 
have pre-existing congestive heart failure or chronic 
lung disease. Both procedures were done across 412 
hospitals. Both procedure types were performed at 
222 of the hospitals encompassing 5573 of the admis-
sions; 177 sites performed open AAA repair only (915 
admissions), and 13 sites (28 admissions) performed 
only EVAR. The median number of procedures per 
hospital was eight.
Exposure, outcome, and covariates
ARF was diagnosed in 439 (6.7%) patients. Endo-
vascular aortic repair was inversely associated with the 
development of ARF. Older age and female gender 
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were significantly associated with ARF, as were the 
presence of chronic kidney disease, congestive heart 
failure, and chronic lung disease. When adjusted for 
covariates, the association between EVAR and the 
risk of ARF remained significant. There were 173 
(2.7%) postoperative deaths. Mortality was higher 
among patients who underwent open repair compared 
with EVAR (3.9% vs 1%). In-hospital mortality was 
markedly higher among patients who developed ARF 
compared with those who did not (18.9% vs 1.6%, 
P<0.0001). After adjustment for procedure type, de-
mographic factors, comorbidity, and hospital related 
factors, ARF remained independently associated with 
mortality (OR, 11.3; 95% CI, 7.6 to 16.8). The asso-
ciation of ARF with mortality did not differ accord-
ing to the type of procedure (P=0.42 for interaction 
term).
Discussion
The findings reported here may help clarify con-
flicting results from other observational studies and 
clinical trials. The Dutch Randomized Endovascular 
Aneurysm Management (DREAM) trial showed that 
postoperative changes in serum creatinine levels were 
similar in patients undergoing EVAR and open AAA 
repair. However, enrolment in this randomized trial 
was limited to centers that performed at least 30 open 
AAA repairs and 50 EVAR procedures annually. 
In addition, the patient population in the DREAM 
study was younger, included fewer women, and had 
a lower frequency of some comorbidities, including 
diabetes and chronic lung disease, compared with the 
cohort we have described.
Whether early initiation of RRT is associated with 
improved survival is unknown, and clear guidelines 
on RRT durations are still lacking. In particular, it 
remains unclear whether hemodynamically unstable 
patients who develop septic shock pre- and postopera-
tively can benefit from early RRT initiation. In addi-
tion, it is not known whether in AKI patients under-
going cardiac surgery, RRT modalities can eliminate 
significant amounts of clinically relevant inflammatory 
mediators. This review gives an update of information 
available in the literature on the possible mechanisms 
underlying AKI and recent developments in continu-
ous RRT modalities.
Prevalence and incidences
Patients who develop ARF following AAA surgery 
have higher rates of mortality and their management 
requires significantly greater resource utilization, par-
Table 2. Summary of most important individual studies (Level of evidence IA – con-
tinuous renal replacement therapy (CRRT) after abdominal aortic aneurysm (AAA) 
repair)
Study References Year Number of patients
Mortality 
(CRRT) Quality score
Mauitz 29 1986 58 75% 3.11
Bartlett 10 1986 56 71.9% 2.63
Simpson 12 1987 32 50.0% 2.47
McDonald 9 1991 42 77.3% 2.40
Kierdorf 27 1991 146    78.1% 2.73
Bosworth 8 1991 320 82.1% 1.92
Bastien 25 1991 66 50.0% 2.20
Bellomo 11 1993 167 59.0% 2.98
Krucynski 28 1993 35 33.3% 2.81
Simpson 30 1993 123 70.8% 2.29
van Bommel 31 1995 94 56.7% 2.85
Mehta 32 1996 166 65.5% 3.24
Overall 1400 68.0% 2.62
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ticularly for those patients on chronic dialysis6. His-
torically, the incidence of ARF is reported to be 5%, 
however, up to 2% of the patients who develop ARF 
would require CRRT7, a mode of treatment that was 
introduced in the 1980s8. The development of mild to 
moderate ARF is also associated with a mortality rate 
of 10%-20%9. Considering the need for aortic surgery 
worldwide, it is of great surprise that to date little at-
tention has been paid to the management of patients 
who develop ARF. ARF is the standard term for an 
abrupt and sustained decrease in renal function result-
ing in retention of nitrogenous (urea and creatinine) 
and non-nitrogenous waste products. Depending on 
the severity and duration of renal dysfunction, this ac-
cumulation is accompanied by metabolic disturbances 
such as metabolic acidosis and hyperkalemia, changes 
in body fluid balance, and effects on many other organ 
systems. In 2004, the Acute Dialysis Quality Initiative 
workgroup proposed a multilevel classification system 
for ARF identified by the acronym RIFLE (risk, in-
jury, failure, loss of kidney function, and end-stage 
kidney disease)10. In the intensive medicine arena, 
several studies have used this consensual definition for 
assessing whether outcomes progressively worsened 
with the severity of AKI11. Ricci et al. recently con-
ducted a literature search from August 2004 to June 
2007 on 24 studies in which the RIFLE classification 
was used to define AKI22. The authors concluded that 
the RIFLE classification is a simple, readily available 
clinical tool to classify AKI in different populations 
and suggested that even mild degrees of kidney dys-
function may have a negative impact on outcome12. 
Furthermore, many of the patients undergoing urgent 
AAA surgery have been undergoing angiography pri-
or to surgery and are exposed to the additional risk 
of contrast nephropathy. Contrast nephropathy has 
been associated with a high cardiovascular mortality 
of nearly 40% without the need for dialysis, and 45% 
when the patient has been on hemodialysis12. 
Risk factors for post-aortic surgery acute renal failure
The causes of renal hypoperfusion and subsequent 
ARF are variable and include pre-existing chronic 
renal insufficiency, older age, previous cardiovascular 
surgery, tissue edema, microembolism, endothelial 
dysfunction, length of aortic cross-clamp time, peri-
operative hypotension, duration of surgery, increased 
generation of reactive oxygen species, pre-existing re-
duction in renal blood flow, pre-existing anemia, co-
existing morbidities such as hypovolemia, congestive 
heart failure, requirement of vasopressure support, 
and exposure to nephrotoxic agents/drugs (aminogly-
cosides, vancomycin, contrast dye) in the immediate 
preoperative period13-18. Although numerous variables 
were identified as predictors of AKI, information is 
still lacking regarding the specific risk factors associ-
ated with the level of preoperative renal function19,20. 
The possible mechanisms of post-aortic surgery acute 
renal failure
The development of AKI as the result of renal 
ischemia depends on the degree and duration of the 
ischemic event and functionality of the countervail-
ing mechanism. Prolonged renal arteriolar vasocon-
striction is perpetuated by hypovolemia, dehydration, 
increased levels of vasoconstrictors (adenosine, angio-
tensin, aldosterone, endothelin, catecholamines, and 
thromboxanes) as well as a decrease in atrial natriuretic 
peptide (ANP) and nitric oxide-dependent renal va-
sorelaxation13,14,20. For example, endothelial dysfunc-
tion of diabetic renal vasculature is characterized by 
an impaired nitric oxide-dependent and prostaglan-
din-dependent vasorelaxation14,15. Hence, adenosine-
induced vasoconstriction of the afferent arterioles, 
which occurs as the result of mitochondrial ATP 
hydrolysis during renal ischemia, is markedly exacer-
bated in diabetic renal vasculature and causes a much 
more profound ischemia-induced reduction of renal 
blood flow when compared with non-diabetic condi-
tions. This apparent increase in the risk of developing 
AKI in the diabetic milieu is linked to a higher sen-
sitivity of the renal vasculature to adenosine-induced 
renal vasoconstriction via adenosine A1 receptors, as 
the result of a diminished renal prostaglandin- and ni-
tric oxide-dependent vasodilatory capacity16-18,20. 
Continuous renal replacement (CRRT) therapy for 
postoperative acute renal failure
CRRT is subdivided into venovenous and arterio-
venous categories; it offers continuous and steady fluid 
removal and uremic toxin clearance. Previously pub-
lished studies have revealed that hemofiltration im-
proves heart and lung functions in patients with ARF 
and cardiac shock after cardiovascular surgery21,22. 
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This can reduce the need of inotropic support, which 
contributes to patient survival22,23. This method pro-
vides better control of fluid status, improves uremia, 
and also ultrafiltrates toxic proteins such as myocardial 
depressant factors. CRRT also helps in improving the 
ventricular function by restoring the myocardial water 
content (MWC) within the normal limits23. 
Continuous venovenous hemofiltration
Continuous hemofiltration with the aid of a blood 
pump provides solute removal by convection. It offers 
high volume ultrafiltration using replacement fluid, 
which can be administered pre-filter or post-filter. The 
pump guarantees adequate blood flow to maintain 
required ultrafiltration rates. Venous blood access is 
usually femoral, jugular or subclavian using a double 
lumen cannula. This mode is used for removal of fluid 
and middle-sized molecules (Fig. 1).
Continuous venovenous hemodialysis (CVVH)
These are new modifications of continuous re-
placement therapy, most useful in patients who are he-
modynamically compromised. This technique uses an 
infusion pump, hemodialysis membrane and dialysate 
solution as well as the same blood access circuitry as 
the CVVH technique. The use of a pump-driven ven-
ovenous circuit in this technique permits blood flows 
that are both higher and more constant than those 
provided by an arteriovenous circuit. In addition, the 
elimination of the need for a large bore arterial cath-
eter eliminates the associated risks of arterial throm-
bosis and arterial bleeding (Fig. 2).
Fig. 1. Continuous venovenous hemofiltration. Continu-
ous hemofiltration with the aid of a blood pump provides 
solute removal by convection. It offers high volume ul-
trafiltration using replacement fluid, which can be ad-
ministered pre-filter or post-filter. The pump guarantees 
adequate blood flow to maintain required ultrafiltration 
rates. Venous blood access is usually femoral, jugular or 
subclavian using a double lumen cannula.
Fig. 2. Continuous venovenous hemodialysis. This tech-
nique uses an infusion pump, hemodialysis membrane and 
dialysate solution. As with the continuous arteriovenous 
hemodialysis system, adding the dialysis membrane and the 
dialysate solution increases the efficiency of the procedure. 
The process of continuous diffusion dialysis in continuous 
venovenous hemodialysis is less effective than continuous 
arteriovenous hemodialysis because the lower pressure ve-
nous system does not filter as much blood per unit of time. 
The use of a pump-driven venovenous circuit in continu-
ous venovenous hemodialysis permits blood flows that 
are both higher and more constant than provided by an 
arteriovenous circuit. In addition, the elimination of the 
need for a large bore arterial catheter eliminates the as-
sociated risks of arterial thrombosis and arterial bleeding. 
A = double-lumen subclavian vein access; B = venous air 
trap; C = venous pressure monitor; D = air detector; E = 
dialyzer; x,y,z = blood and dialysate pumps.
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Continuous venovenous hemodialfiltration
This approach utilizes a blood pump and venous ac-
cess site for removal of solutes by diffusion and convec-
tion simultaneously. It offers high volume ultrafiltration 
using replacement fluid, which can be administered pre-
filter or post-filter. Simultaneously, dialysate is pumped 
in counter flow to blood. This mode is used where large 
amounts of fluid are removed and replaced per hour, as 
a means of ‘cleaning’ the plasma, for example to remove 
inflammatory cytokines (Fig. 3). 
Continuous arteriovenous hemodialysis (CAVHD) 
This is a continuous diffusion process of remov-
ing uremic toxins from blood into a sterile dialysate 
fluid. Blood flows spontaneously through an AV shunt 
or femoral cannulation of an artery and vein. Blood 
and dialysis fluid flows are counter-current to maxi-
mize diffusion. This technique was developed to aug-
ment the solute clearances obtainable with continuous 
arteriovenous hemofiltration. This modality is similar 
to continuous venovenous hemodialysis, with one ex-
ception: the addition of the continuous perfusion of 
dialysate through the hemofilter counter-current to 
the direction of blood flow, most commonly at a rate 
of 1–2 L/h. As a result, technical requirements for sat-
isfactory performance of CAVHD are similar to those 
of continuous venovenous hemodialysis (Fig. 4).
Benefits of continuous renal replacement therapy in 
maintaining post-surgery hemodynamic stability
While scientific criteria for the initiation of re-
nal replacement therapy in ARF patients have not 
yet been defined, most renal physicians believe it is 
reasonable to prefer modalities that prevent physi-
ological derangements as opposed to that of post-hoc 
correction. Although recommended for ARF, perito-
neal dialysis (PD) is not suitable for adult critically ill 
patients because of the high rates of associated peri-
toneal infections and poor to inadequate solute clear-
ance leading to less than optimal uremic controls21. 
PD also impedes diaphragmatic movements and is 
associated with pulmonary and cardiac dysfunction. 
Overall, intermittent hemodialysis is associated with 
hemodynamic instability and therefore hemofiltration 
is considered a safer modality for treatment of ARF 
patients22,23. Compared with other forms of uremic 
therapies, volume control is continuous and adaptable 
to the changing circumstances during CRRT. CRRT 
avoids swings in the intravascular volumes, maintains 
Fig. 3. Continuous venovenous hemodialfiltration. Con-
tinuous hemodialfiltration with the aid of a blood pump 
provides solute removal by diffusion and convection si-
multaneously. It offers high volume ultrafiltration using 
replacement fluid, which can be administered pre-filter or 
post-filter. Simultaneously, dialysate is pumped in counter 
flow to blood.
Fig. 4. Continuous arteriovenous hemodialysis. This tech-
nique uses an infusion pump, hemodialysis membrane 
and dialysate solution as well as the same blood access cir-
cuitry. An infusion pump pushes a continuous trickle of 
sterile dialysis fluid into the dialysate compartment of the 
hemodialyser membrane. The blood/dialysate interface is 
the hemodialysis membrane. This method uses the process 
of continuous diffusion dialysis to rid the body of fluid, 
electrolytes, and nitrogenous wastes. The preferred arterial 
access site is the common femoral artery.
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blood pressure and prevents treatment-associated renal 
injury. Thus, CRRT achieves a much superior uremic 
control when compared with other forms of treatment 
for renal impairment24. CRRT also allows a greater 
metabolic control to be achieved and thus provides 
a platform for an aggressive, protein rich nutritional 
policy to improve daily nitrogen balance, thus having 
possible favorable effects on the immune function and 
overall outcome22-24. 
Elimination of inflammatory cytokines and 
anaphylatoxins by continuous renal replacement 
therapy
CRRT has added pumps to increase the filtration 
rates and sometimes combines primarily convective 
compound transport (by hemofiltration) with diffusive 
transport (with an additional dialysis cycle) across a hy-
drophobic membrane. Hydrophobic membranes have 
an asymmetric structure, allowing solutes of a wide 
range of molecular weights (cut-off 30 kDa) to be elim-
inated by convection. TNF-alpha (MW 52 kDa), a key 
mediator of sepsis, is unlikely to pass the commonly 
used filters owing to the size. Clinical studies have 
given conflicting evidence of its removal, with some 
studies suggesting no changes in the plasma TNF-
alpha level and others showing substantial to minimal 
clearance25-28. Some studies have shown an increase in 
the plasma levels due to the passage through the hemo-
filter29. The plasma levels of TNF-alpha change during 
the course of illness and therefore depend on the time 
of CRRT initiation as well as on the amount elimi-
nated by hemofiltration. Similarly, contradictory results 
exist for interleukin-6 (IL-6), MW 26 kDa, with some 
studies showing its presence in dialysis effluents30, while 
others showing no IL-631. Recent prospective studies 
have shown that CRRT does not have a significant im-
pact on serum IL-6 levels despite significant transfer of 
IL-6 from blood into dialysate32. Other studies demon-
strated that CRRT with high-volume hemofiltration (8 
L/h) improved the cardiac index, which was related to 
improved survival32.
Timing of continuous renal replacement therapy on 
operative outcomes
Although there is continuing debate on the under-
lying mechanisms by which CRRT improves survival, 
there is also no international consensus on important 
issues such as the indication for  and timing of initia-
tion of CRRT due to the absence of relevant guide-
lines and an international consensus on the definition of 
ARF33. Until recently, it was not known whether small 
subtle changes in renal function could have an impact 
on operative outcomes. To address this, Mangos et al. 
studied the association between small serum creatinine 
changes after surgery and mortality, independently of 
other established perioperative risk indicators10. The au-
thors suggested that even a mild change in the renal 
function may have an effect on the operative outcomes 
and then concluded that elevated creatinine may be an 
independent indicator for the risk of death. In another 
study, Schiffl et al. report on the effect of daily inter-
mittent hemodialysis as compared with conventional 
(alternate-day) intermittent hemodialysis, on survival 
among patients with acute renal failure34. It was found 
that less frequent hemodialysis (on alternate days as op-
posed to daily) was an independent risk factor for death. 
In contrast, Sander et al. studied the effects of the ini-
tiation time of continuous venovenous hemofiltration 
and of the ultrafiltrate rate in patients with circulatory 
and respiratory insufficiency developing early oliguric 
ARF35. The authors concluded that survival and recov-
ery of renal function were not improved by using high 
ultrafiltrate volumes or early therapy initiation. Other 
recent studies, however, have shown that the introduc-
tion of CRRT early in the course of treatment may 
improve survival15,17. Not many studies have looked at 
the outcome of postoperative renal dysfunction with or 
without the need of CRRT and the long-term outcome. 
A recent study by Sanchez Izquierdo et al. investigated 
in-hospital and long-term prognosis of patients with 
postoperative renal deterioration36. None of the survi-
vors in their study developed end-stage renal disease, 
however, details on the timing of CRRT initiation and 
levels of long-term renal function were not provided, 
making it difficult to ascertain whether the episodes of 
ARF were associated with a progressive decline in re-
nal function and also whether early initiation of CRRT 
had any beneficial effects on patient survival. 
Effect of duration and intensity of continuous renal 
replacement therapy
Some recently published randomized studies have 
failed to demonstrate outcome improvement with more 
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intense RRT37,38.  Bellomo et al. studied critically ill 
patients with acute kidney injury requiring intensive 
renal support in terms of mortality, improvement in 
recovery of kidney function, or reduction in the rate 
of non-renal organ failure as compared with less-in-
tensive therapy involving a defined dose of intermit-
tent hemodialysis three times per week and continuous 
RRT at 20 mL/kg/h37. The results appear to suggest 
the possibility that the duration of applying intense 
versus less-intense RRT did not affect the outcomes. 
Tonnesen et al. studied the effect of the CVVHDF 
dosage on survival in ARF patients39. The observa-
tions in these studies raise concerns as to the issues 
surrounding the definition of ARF, whether inap-
propriate patient selection criteria were used, whether 
results from different treatment modalities are com-
parable in different patient groups, and whether the 
studies were adequately powered.
Limitations of the study
As electronic databases are administrative data 
sources, we could not adjust for confounding by an-
eurysm location or structure40. Information bias is 
an important limitation of this study. The ascertain-
ment of ARF is particularly susceptible to misclas-
sification. Central to this problem is the absence of 
a universally accepted definition of ARF. The lack of 
clear criteria for the assignment of an ARF diagnosis 
(and a subsequent diagnostic code for ARF) leads to 
a situation where coding practices, rather than clini-
cal reality, may guide the inclusion of ARF in a dis-
charge summary. This source of information bias is 
likely to be nondifferential because there is no reason 
to expect that the accuracy of ARF coding should 
differ between the procedure types. Nondifferential 
misclassification would bias the association toward 
the null. It is also reassuring that the rate of ARF in 
patients undergoing open AAA repair was similar to 
that reported in previous series1-3. Finally, since the 
administration of hemodialysis for ARF is unlikely to 
be coded inaccurately, it is notable that the protective 
effect of EVAR on the outcome of ARF requiring he-
modialysis paralleled the impact of procedure type on 
the development of ARF overall.
A further source of differential information bias 
is rooted in the differing lengths of stay in the two 
groups. Given a markedly shorter length of stay in the 
EVAR group, it is conceivable that clinical evidence 
of AKI developed after discharge in some EVAR pa-
tients, which would not be captured in this database. 
As contrast nephropathy usually becomes apparent 
within 24 to 48 hours of the procedure42,43, under-as-
certainment of ARF among EVAR recipients whose 
length of stay was ≤2 days may have occurred. Un-
fortunately, the NIS does not permit the assessment 
of post-discharge data and because each discharge – 
rather than the actual patient – it is assigned a spe-
cific identifier, information on readmissions for ARF 
would be unobtainable. However, we estimated that 
among EVAR patients discharged within 2 days, 
ARF incidence would have to surpass 5% for EVAR 
to lose its relative protective effect. Because this fig-
ure exceeds reported rates for post-EVAR ARF, it is 
unlikely that this form of misclassification would be 
substantial enough for the inverse association between 
EVAR and ARF to be lost.
Further studies
It is disappointing that CRRT has been a therapeu-
tic option in critical care practice for over 20 years with-
out definitive evaluation of its benefits. While recent 
clinical trials have shown reduced all-cause mortality 
with changes in other forms of supportive care such 
as mechanical ventilation43, it is possible that chang-
ing dialysis modality will also reduce mortality. Our 
analysis suggests that a definitive CRRT to AAA sur-
gery trial would require roughly more than 1000 pa-
tients for beneficial results. Such a trial should control 
for factors such as membrane and co-interventions and, 
based on recent evidence43-47, should consider treat-
ment dose, perhaps in factorial design with treatment 
modality. Efforts should be made to limit crossovers 
between treatment modalities. Finally, it would seem 
to be important to stratify randomization on the pres-
ence or absence of hemodynamic instability because 
this is the major determining variable for who receives 
CRRT in practice. Nevertheless, we suggest that such 
a trial is necessary and, in the meanwhile, CRRT 
should be made available to at least some patients with 
ARF. To develop a predictive score for ARF follow-
ing abdominal aortic surgery, we need to improve indi-
vidualized patient care focuses on the identification of 
early predictive biomarkers such as urine neutrophils, 
gelatinase-associated lipocalin, urinary IL-8, and liver 
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fatty acid-binding protein38,39,48,49. Future studies could 
be designed to identify high-risk individuals based on 
standardized score. This could lead to initiation of time-
ly interventions that might prevent or ameliorate renal 
injury and improve operative outcomes. A key element 
is dissemination of information across the continuum 
of care. This calls for multidisciplinary collaboration 
among cardiovascular surgeons, nephrologists, and al-
lied personnel involved in patient care who may not be 
aware of study findings published in selective society 
journals50-53. This has thus far limited the adaptation of 
study findings into clinical practice. We conclude that 
future progress in this area will depend primarily on 
the choices we make now. 
Conclusion
This study provides important information on the 
renal safety of a novel approach to the repair of AAAs. 
Compared with open AAA repair, our findings sug-
gest that EVAR is associated with a lower risk of post-
procedure ARF. These results reflect the outcomes of 
actual practice in a heterogeneous and unselected pa-
tient population that received care in a wide spectrum 
of renal therapies.
Observations from the presented studies reinforce 
the notion that there are many unresolved issues re-
lated to postoperative ARF. The time has come for the 
implementation of a consensus on the standard defini-
tion of ARF that is sensitive and specifically defines 
this complication. This will permit an accurate as-
sessment of the impact of ARF on outcomes, and al-
low comparison of patients across centers worldwide. 
The preoperative risk assessment scores will need to 
be re-validated prospectively using the standardized 
definitions and should incorporate emerging knowl-
edge of patient characteristics and care elements. In 
this regard, a prognostic score system for AKI would 
help anticipate patient treatment. As EVAR becomes 
a more widely practiced procedure, strategies to fur-
ther reduce procedure-related kidney injury should be 
diligently investigated.
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Sažetak
ZAMJENSKE BUBREŽNE TERAPIJE NAKON KIRURŠKOG LIJEČENJA ANEURIZME ABDOMINALNE 
AORTE – PREGLEDNI ČLANAK
N. Hudorović, I. Lovričević, P. Brkić, Z. Ahel i V. Vičić-Hudorović
Danas postoje brojni oblici zamjenske terapije u svrhu liječenja akutne bubrežne bolesti poslije kirurškog liječenja 
aneurizme abdominalne aorte. Cilj ovoga preglednog članka je utvrditi učestalost poslijeoperacijskog akutnog zatajenja 
bubrega koje iziskuje uporabu hemofiltracijskih postupaka te utvrditi čimbenike koji utječu na ishod liječenja bolesnika 
poslije kirurškog liječenja aneurizme abdominalne aorte. Stupanj težine združenih bolesti, etiologija akutne bubrežne 
bolesti, klinički i hemodinamski čimbenici bolesnika, veličina raspoloživih materijalnih sredstava, te troškovi terapije 
imaju izravan utjecaj na odabir i vrstu zamjenske terapije za liječenje akutne bubrežne bolesti. Postoje različita mišljenja o 
svrsishodnosti uporabe zamjenske terapije za liječenje akutne bubrežne bolesti. Nadalje, do danas su nedostatno opisane 
smjernice o potrebnom trajanju zamjenske terapije za liječenje akutne bubrežne bolesti. Nedostatno je razjašnjeno kakva 
je učinkovitost zamjenske bubrežne terapije kod hemodinamski nestabilnih bolesnika kod kojih nastaje akutna bubrežna 
bolest neposredno prije i poslije operacijskog zahvata. Također, nedostatno je poznavanje učinkovitosti mehanizama dje-
lovanja zamjenskih bubrežnih terapija u smislu odstranjenja štetnih proizvoda metabolizma bubrega. U ovom preglednom 
članku opisuju se najnovija saznanja o mehanizmima i djelovanju te vrstama zamjenskih bubrežnih terapija koje su danas 
u uporabi kod bolesnika kod kojih se razvija akutna bubrežna bolest poslije kirurškog liječenja aneurizmatske bolesti ab-
dominalne aorte. 
Ključne riječi: Bubreg, transplantacija; Akutno bubrežno zatajenje; Oksidacijski stres; Aneurizma abdominalne aorte
